**6. Conclusions**

Recently, the results of a GWAS—a study aimed to determine personalised RA therapy based on the genetic polymorphisms associated with sensitivity to FDA-approved antirheumatic drugs—have been published. Moreover, epigenetic changes (including microRNA polymorphism and expression) altering the disease complication risk and response to treatment should be taken to account, along with the germline variants assessment for RA predisposition and therapy response [96,97]. In that way, researchers are striving to develop a genetic testing algorithm for DMARD therapy personalisation to make RA treatment more clinically- and cost-effective. Thus, the published results of original scientific studies, reviews, and meta-analyses allow us to characterise the genetic component of RA predisposition in various populations and emphasise specific variants to be analysed for the most effective treatment regimens.

**Author Contributions:** Conceptualization, D.S.M., M.V.N., I.V.B., V.V.T., A.N.L., E.A.A. and A.A.Z.J.; writing—original draft preparation, D.S.M, I.V.B., E.B.K., M.I.B. and A.A.D.; writing—review and editing, D.S.M., M.V.N., E.B.K. and A.A.Z.J.; project administration, A.A.Z.J.; funding acquisition, A.A.Z.J. All authors have read and agreed to the published version of the manuscript.

**Funding:** The authors received funding from the Ministry of Science and Higher Education of the Russian Federation, Ref. No. RFMEFI60518X0003, for this work.

**Conflicts of Interest:** The authors declare no conflict of interest.
